Highlights from the 2015 “Business of Regenerative Medicine” course

Author: Guest, 08/27/15

. Nadia Houri is a Business Development Analyst with the Centre for Commercialization of Regenerative Medicine (CCRM).   Last month, I had the pleasure of attending The Business of Regenerative Medicine: Cells at Work course, hosted by Georgia Tech, in Atlanta. With two and a half very full days of lectures and networking opportunities, cells…Read more

Update from the Clinic: July

Author: Mark Curtis, 08/25/15

. Welcome to your update from the Clinic for the month of July. Adaptimmune moves a second candidate into the clinic. Ziopharm receives an Orphan Drug Designation for its cutting edge IL-12 technology. Canadian cell therapy company, Hemostemix, keeps moving forward with enrolment in its clinical trial for ACP-01 in critical limb ischemia. Oxford-based Adaptimmune…Read more

Right Turn: This is not a One Direction concert review

Author: Stacey Johnson, 08/21/15

. Last night, I took my daughters to a One Direction concert. Regardless of what you might now think of me (us), they still have several (million) fans around the world. The 40,000 screaming girls in attendance at the Rogers Centre showed the Brit boys lots of love. Anyhoo, earlier this week I was trying…Read more

Cell Therapy Deal Review: July

Author: Mark Curtis, 08/18/15

. Welcome to your Cell Therapy Deal Review for the month of July. Here at Signals we’ve decided to change the name of this monthly column, to pay consideration to the fact the majority of the technologies discussed here are cell-based. Moving forward, I will continue to focus on the cell therapy industry specifically, but…Read more

Right Turn: George Daley on The Stem Cell Podcast

Author: Stacey Johnson, 08/14/15

. Do you listen to The Stem Cell Podcast? If not, why not? Last September, former Signals co-editor Lisa Willemse blogged about the podcast, which, at the time, was celebrating its first anniversary. The hosts and creators behind the podcast are celebrating another milestone: their 50th episode. For this special occasion, they interviewed George Daley…Read more

Q. What do cyborg beetles and the smart bandage have in common? A. An innovative researcher.

Author: Hamideh Emrani, 08/10/15

. In her series “What drives research in the field of biomaterials?” blogger Hamideh Emrani interviews a third highly respected biomaterials researcher. You can read her interviews with Professors John Davies and Craig Simmons (University of Toronto) here and here. My last post was about an exciting development called the smart bandage. I was visiting…Read more

Right Turn: #ILookLikeAnEngineer

Author: Stacey Johnson, 08/07/15

. First female scientists were #DistractinglySexy – and hilarious, I might add. (If this means nothing to you, I recommend you read this article for a good recap.) Now their female engineering friends and colleagues are also tackling sexism in STEM – science, technology, engineering and math – with their own Twitter hashtag: #ILookLikeAnEngineer. For…Read more

Avoiding ‘wrinkles in time’: Using tissue engineered grafts to model skin aging

Author: Holly Wobma, 08/06/15

. This is not a blog about cosmology, nor the space-time continuum or our place in the universe. As much as I love these deep topics, today I’d like to discuss something, quite literally, more superficial: the aging of human skin. As with other organs in our body, skin undergoes many changes as we get…Read more

Right Turn: Putting your money where your mouth is

Author: Stacey Johnson, 07/31/15

. Tomorrow (or today for you readers), I’m heading to a BBQ. Canadians love to BBQ. I don’t have any stats on this, but I was born in Canada and I know this to be true. To further support my statement, Google says Canada “leads the world when it comes to online searches for recipes…Read more

Regenerative Medicine Deal Review: June

Author: Mark Curtis, 07/29/15

. Welcome to your Regenerative Medicine Deal Review for the month of June. It was an epic month in partnerships that saw multiple collaborations closely tying industry leaders together. Almost all public cell-based immunotherapy companies have formed partnerships with Big Pharma or biotech in the last 24 months, amongst a flurry of collaborative activity that…Read more